Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
Finland
Novartis Investigative Site, Kuopio Novartis Investigative Site, Turku France
Novartis Investigative Site, Lille Novartis Investigative Site, Paris Novartis Investigative Site, Toulouse Spain
Novartis Investigative Site, Valencia, Valencia Novartis Investigative Site, Barcelona Novartis Investigative Site, Barcelona Sweden
Novartis Investigative Site, Malmo Novartis Investigative Site, Stockholm